New Weight-Loss, Diabetes Drugs Reach One in Eight Americans [BNN Bloomberg (Canada)]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: BNN Bloomberg
Of those who've tried the drugs, about half are currently still taking them, according to a poll from health research organization KFF released Friday. Drugs including Eli Lilly & Co.'s Mounjaro and Zepbound and Novo Nordisk A/S's Ozempic and Wegovy are deepening their reach into the US population where rates of diabetes and obesity have escalated for decades. Yet cost remains a barrier: More than half of respondents who tried the medications said they're difficult to afford, even with coupons and insurance coverage. A monthly supply of Ozempic costs almost $1,000 before discounts or rebates. More than half of people on the drugs with health insurance said insurance covered part of the cost, while a quarter said insurance paid in full, according to the KFF poll. The nonprofit routinely polls Americans on their views about health topics. The medications known as GLP-1s were originally developed to treat diabetes but also helped people taking them lose weight. More recently, some
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Hims Debuts $199 Weight-Loss Shots at 85% Discount to Wegovy [BNN Bloomberg (Canada)]BNN Bloomberg
- The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control [Yahoo! Finance]Yahoo! Finance
- Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Stanley Druckenmiller makes surprising small-cap and AI stock bet [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 4/30/24 - Beat
LLY
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form SD
- 4/30/24 - Form 10-Q
- LLY's page on the SEC website